According to CoinMeta, Yuekang Pharmaceutical announced that its subsidiary, Yuekang Kechuang, has recently received approval from the US FDA to conduct clinical trials for the use of YKYY018 nebulized inhalant in the treatment and prevention of human parainfluenza virus infections, with trial number IND 183460. The YKYY018 nebulized inhalant is an internationally original membrane fusion inhibitor drug independently developed by the company using a full-process AI platform. Previously, it has already obtained approval from FDA and NMPA to carry out clinical trials for respiratory syncytial virus and human metapneumovirus infections. Currently, the II phase clinical research for respiratory syncytial virus infections is underway. This approval further expands the clinical application of this product in the field of respiratory virus infection prevention and treatment, although there is uncertainty regarding the subsequent research and development and approval outcomes of the drug.